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ABSTRACT 
Objective: This study aimed to investigate the relation between vitamin D plasma concentrations and prevalence of prespecified coronary risk 
factors, and to assess the role of vitamin D deficiency as an independent risk factor for the acute coronary syndrome (ACS). 
Methods: In this study, plasma 25-hydroxyvitamin D [25(OH)D] levels were measured in 60 consecutive ACS patients at hospital presentation, and 
patient data including socio-demographics and clinical variables were recorded at the time of admission. We used the Independent samples T-test 
and the chi-square test to compare differences in the continuous and categorical variables, respectively. The partial correlation coefficient was used 
to measure association between plasma vitamin D levels and acute coronary syndrome while controlling for traditional cardiovascular risk factors. 
Results: This study found significant associations between low plasma vitamin D levels and prevalence of hypertension and smoking. Whereas, no 
significant association between low plasma vitamin D levels and prevalence of diabetes mellitus (DM) was found. There was a statistically 
significant correlation between vitamin D deficiency and acute coronary syndrome, even after controlling for traditional cardiovascular risk factors 
(P = 0.028). 
Conclusion: Vitamin D deficiency is independently associated with acute coronary syndromes, and could be an independent risk factor for the acute 
coronary syndrome (ACS). 
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Vitamin D is a major regulator of mineral ion homeostasis. Its 
deficiency is best known to cause rickets, osteomalacia and 
osteoporosis. Recent data, however, indicate broader roles for 
vitamin D in various biological processes through its active form, 
calcitriol or 1α, 25-dihydroxyvitaminD [1α,25(OH)2D] [1]P. Low 
levels of 25-hydroxyvitamin D [25(OH)D], the principal circulating 
storage form of vitamin D, are present in as many as one third to one 
half of otherwise healthy middle-aged to elderly adults [2-5]. 
Limited cutaneous synthesis due to inadequate sun exposure or dark 
skin and inadequate dietary intake are the principal causes of low 
25(OH)D levels. 
Vitamin D, known primarily as a hormone of bone metabolism, can 
affect the transcription of a number of genes which play a pivotal role 
in both the development of acute coronary syndromes and the 
pathogenesis of coronary artery disease (CAD) [6]. In addition, vitamin 
D may inhibit the renin-angiotensin system [7], reduce parathyroid 
hormone levels [8], decrease coagulation [9], reduce inflammation 
[10] thereby reducing atherosclerosis, and increase insulin production 
[11, 12]. Epidemiologic studies have also recently linked vitamin D 
deficiency with increased risk of major adverse cardiovascular (CV) 
events [13]. A study of male health professionals showed a 2-fold risk 
of myocardial infarction (MI) in subjects who were vitamin D deficient 
compared with those in the sufficient range [14].  
It has been recently reported that Vitamin D deficiency is common in 
patients with acute coronary syndromes (ACS) in Syria [15]. Early 
reports have linked Vitamin D deficiency to such cardiovascular (CV) 
conditions as hypertension, diabetes mellitus, obesity and the 
metabolic syndrome, left ventricular hypertrophy, heart failure, 
coronary heart disease, renal disease, and mortality [8, 14, 16-19]. 
However, a systematic review of 13 observational studies examining 
the association of vitamin D status with cardio-metabolic outcomes 
(type 2 diabetes, hypertension, or cardiovascular disease) concluded 
that the association is uncertain and the results were hampered by 
the heterogeneity of studies [20]. 
Because hypovitaminosis D is prevalent and readily treatable, 
establishing the relationship between vitamin D and risk of ACS is 
important. Thus, we examined plasma 25(OH)D concentrations 
relation to coronary risk factors, and assessed the role of vitamin D 
deficiency as an independent risk factor for the acute coronary 
syndrome (ACS). 
MATERIALS AND METHODS 
60 consecutive acute coronary syndrome patients admitted to the 
Cardiac Care Unit at affiliated hospitals of Aleppo University in 
Aleppo, Syria, were recruited. According to the European Society of 
Cardiology/American Heart Association redefined guidelines [21], 
patients were classified as ST-elevation myocardial infarction 
(STEMI; n = 30), non-ST elevation myocardial infarction (NSTEMI; n 
= 18) and unstable angina (UA; n = 12). A written informed consent 
was taken, and patient data including socio-demographics and 
clinical variables including hypertension, peripheral arterial disease, 
diabetes mellitus, previous AMI, previous angina, family history of 
coronary artery disease, and smoking history were recorded at time 
of admission. Hypertension was defined as systolic blood pressure ≥ 
140 mmHg, diastolic blood pressure ≥ 90 mmHg, or use of 
antihypertensive therapy [22]. Criteria for diabetes mellitus were a 
fasting glucose ≥126 mg/dl, use of  insulin or hypoglycemic 
medications [23]. Active smoking was defined as current use of 
cigarette, hookah or pipe. Patients with renal diseases, hepatic 
diseases, or malignancy, those on phenytoin or other medications that 
can affect vitamin D and calcium metabolism like corticosteroid and 
bisphosphonates drugs, or who had recently received vitamin D or 
calcium supplements during the last three months, and patients who 
refused or unable to give consent were excluded from the study. 
Blood samples for analysis were collected in liquid Lithium Heparin 
blood tubes on patient admission to the cardiac unit. Plasma was 
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obtained immediately by centrifuging blood tubes (3000 G for 10 
min), and frozen at–20 °C until further assessment. creatine kinase-
MB and troponin T levels were analyzed quantitatively by an electro 
chemi-luminescence technology using Cobas e411 module (Roche 
Diagnostics, Mannheim, Germany). Total vitamin D plasma level was 
measured by using a competitive solid phase enzyme-linked 
immunosorbent assay (competitive ELISA) (DiaMetra, Pozzulo, 
Italy). The lowest detectable concentration of 25(OH)D was 0.3 
ng/ml, and no samples showed concentrations below the limit of 
detection. 
Summary statistics are presented as frequencies and percentages for 
the categorical variables and as the mean values±standard deviation 
(SD) for the continuous variables. We used the Independent samples 
T-test and the chi-square test to compare differences in the 
continuous and categorical variables, respectively. The partial 
correlation coefficient was used to measure the association between 
plasma vitamin D levels and acute coronary syndrome while 
controlling for traditional cardiovascular risk factors. The 
prospectively defined risk factors of interest and available to study 
were age, gender, smoking, hypertension, diabetes mellitus, and 
previous cardiovascular diseases. The 25(OH)D cut point of 20 
ng/ml was used in this study [24], that compatible with at least 
moderate vitamin D deficiency. The referent group was prespecified 
as those having 25(OH)D ≥ 20 ng /ml. Although levels of 25(OH)D ˃  
30 ng/ml are considered optimal for bone metabolism, only 5% of 
the study sample had levels in this range. All statistical analysis was 
performed using The Statistical Package for Social Sciences (SPSS 
version 20). A 2-sided probability value<0.05 was considered 
statistically significant. 
RESULTS 
A total of 60 consecutive ACS patients (30 STEMI, 12 UA and 18 
NSTEMI) were included in this study. Selected characteristics and 
biomarker levels of the participants are given in table 1. The study 
subjects mean age was 55.30±10.40 y; men (73.3%) outnumbered 
women (26.7%). 
 
Table 1: Selected characteristics and biomarker levels of the acute coronary syndrome patients 
Variables  ACS patients (N=60) 
Age (years) 55.30±10.40 
Male/Female 44(73.3%)/16(26.7%) 
Hypertension 26 (43.3%) 
Smoking 40 (66.7%) 
Diabetes Mellitus 26 (43.3%) 
Previous Heart Disease 26 (43.3%) 
Vit D (ng/ml) 12.34±9.62 
Troponin T (ng/ml) 1.09±1.37 
CK-MB (ng/ml) 12.66±18.04 
 
Among our patients, forty (66.7%) patients were smokers and the 
mean of plasma 25(OH)D levels was 8.9±7.5 ng/ml in this group. The 
mean of plasma 25(OH)D levels was 19.1±9.8 ng/ml in nonsmoker 
group and the difference between the two groups was statistically 
significant (P value = 0.00). hypertension was present in 26 (43.3%) 
patients and the mean of plasma 25(OH)D levels was 10.09±9.6 ng/ml 
in this group, while the mean of plasma 25(OH)D levels was 
15.09±9.02 ng/ml in patients without hypertension and the difference 
between the two groups was statistically significant (P value = 0.04). 
The difference between the mean plasma 25(OH)D levels in patients 
with DM versus patients without DM was not statistically significant 








Fig. 1: The mean plasma 25(OH)D concentrations in acute coronary syndrome patients; A: between smokers and nonsmokers; B: those 
with and without hypertension; and C: those with and without diabetes mellitus (DM) 
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After controlling for traditional cardiovascular risk factors, the 
association between 25(OH)D deficiency and acute coronary 
syndrome remained significant (P value = 0.02). The patients were 
categorized into two groups according to their plasma 25(OH)D levels; 
25(OH)D levels of ≥ 20 ng/ml were considered normal, while levels 
of<20 ng/ml were classified as deficient. The baseline characteristics 
of cases in these groups are shown in table 2. The only significant 
difference between the two groups of patients was in smoking status. 
 
Table 2: Baseline characteristics of cases according to Vitamin D status 
 
P (value) 
25(OH)D (ng/ml) Variables 
≥ 20 (N=13) 21.7% <20 (N=47) 78.3% 
0.06 49.5±7.6 56.8±10.5 Age (years) 
0.299 11 (84.6%)/2 (15.4%) 33 (70.02%)/14 (29.8%) Male/Female 
0.176 5 (38.5%) 28 (59.6%) Hypertension 
0.000* 3 (23.1%) 37 (78.7%) Smoking 
0.302 4 (30.8%) 22 (46.8%) Diabetes Mellitus 
0.302 4 (30.8%) 22 (46.8%) Previous Heart Disease 
*Statistically significant difference between two groups (P<0.05). 
 
DISCUSSION 
Although the best-characterized sequelae of vitamin D deficiency 
involve the musculoskeletal system, a growing body of evidence 
suggests that low levels of vitamin D may adversely affect the 
cardiovascular system [25]. In parallel, the recognition of the 
presence of widespread vitamin D deficiency is increasing [8, 16, 
26]. Recurrent predictors of hypovitaminosis D throughout the 
Middle East are older age, female sex, multiple births, conservative 
dress, lower-income group, and urban living [27]. The consequences 
of this growing epidemic of vitamin D deficiency are still not well 
understood. However, recent reports of the associations of vitamin D 
deficiency with multiple CV conditions have been of great interest, 
suggesting the need for prospective validation and extended 
observations. 
In this study, vitamin D deficiency was more common in the smoker 
groups and the effect of smoking on vitamin D metabolism may be 
one probable reason. Mechanisms by which smoking affects vitamin 
D metabolism are still unclear. One possibility is that chemicals in 
tobacco smoke may have a direct effect on vitamin D metabolism 
and function, like an accumulation of cadmium in the kidney [28]. 
In accordance to our study, Vitamin D deficiency has been shown to 
be associated with significant increase in the prevalence of 
hypertension, and this was in agreement with previous studies [29]. 
In the study of Forman et al. [30], during 4 y of follow-up, men and 
women who had plasma 25(OH)D levels<15 ng/ml were 3 times as 
likely to have a new diagnosis of hypertension in the next 4 y 
compared with those with 25(OH)D levels>30 ng/ml. Of the 
potentially relevant mechanisms, vitamin D deficiency activates the 
renin-angiotensin-aldosterone (RAAS) system, and excessive RAAS 
stimulation is associated with hypertension. Animal studies [7] show 
that vitamin D is an important regulator of the RAAS system and that 
1,25-dihydroxyvitamin D, the activated form of vitamin D, 
suppresses renin gene expression. Disruption of the vitamin D 
receptor gene leads to elevated renin production, cardiac 
hypertrophy, and elevated blood pressure in mice [31]. 
In this study, we found no significant association between mean 
plasma vitamin D levels of ACS patients with diabetes mellitus in 
comparison with ACS patients without diabetes mellitus. Results 
relating vitamin D deficiency with glucose metabolism have been 
inconsistent. Chiu et al. [11] and Grimnes et al. [32] have found that 
hypovitaminosis D was associated with both decreased insulin 
secretion and insulin sensitivity, while de las Heras et al. [33] 
reported no such relationship. As recently reviewed by Alvarez et al. 
[34], many epidemiological studies have been reported that a low 
plasma vitamin D concentration may be associated with insulin 
resistance. However, in these studies, comparison groups were 
usually not well-matched for potential confounding factors such as 
age, race, BMI, obesity and physical activity. It should also be kept in 
mind that vitamin D deficiency in diabetic patients may partly be a 
consequence of reduced physical activity and consecutive obesity, as 
well as limited sun exposure. Therefore, residual confounding in 
observational studies due to the close link of obesity with both 
vitamin D deficiency and glucose intolerance cannot be ruled out 
with certainty [35, 36]. 
Our data suggest that vitamin D deficiency is associated with 
increased acute coronary syndrome risk, above and beyond 
established cardiovascular risk factors. We controlled for the 
traditional cardiovascular risk factors, including age, gender, 
smoking, hypertension, diabetes mellitus, and previous 
cardiovascular diseases. The results showed that the association 
between 25(OH)D deficiency and acute coronary syndrome 
remained significant (P = 0.02). Also, we studied the strength of this 
relation at cut-point for vitamin D levels (<20 ng/ml) that 
compatible with at least moderate vitamin D deficiency. With this 
cut-point, the prevalence of vitamin D deficiency in the present 
cohort (78.3%) was a considerable high but consistent with that 
reported in other epidemiological studies [24]. In the study of Lee et 
al. [37], the prevalence of vitamin D deficiency in the patients with 
plasma 25(OH)D levels<20 ng/ml was up to (74.9%). In addition, 
with this cut-point we did not find significant differences between 
the plasma vitamin D levels and traditional cardiovascular risk 
factors, except for smoking there was a significant correlation (P = 
0.00) due to the fact that smoking is considered a risk factor for 
vitamin D deficiency. The results of the current study are in 
accordance with the previous studies in the other countries. A 
prospective case-control study in the USA, of more than 18.000 men 
[14] found a statistically significant correlation between low 
25(OH)D levels and an increased risk for myocardial infarction, even 
after adjustment for traditional cardiovascular risk factors. Severe 
vitamin D deficiency has been shown to be independently associated 
with in-hospital cardiovascular mortality in patients with acute 
coronary syndromes [38].  
Clinical studies support a role for vitamin D in maintaining 
cardiovascular health through both the direct action of the vitamin D 
on cardiomyocytes and the indirect actions on circulating hormone 
and calcium levels [39]. Since the vitamin D receptor (VDR) is also 
expressed in the cardiomyocytes and vasculature, it is tempting to 
hypothesize that vitamin D may protect against atherosclerosis, 
vascular calcification and endothelial dysfunction [40]. It inhibits 
cardiomyocytes and smooth muscle cells proliferation [41]. In 
addition, Vitamin D has some anti-hypertrophic effects, suppression 
effect on the renin-angiotensin system, the modulatory effect on 
contractility and regulatory effect on extracellular matrix turnover 
[42]. 
The present study has some limitations, on top of the small size of 
our sample, and the fact that the study was conducted at one centre, 
we couldn’t control for multiple confounders like sun exposure, and 
social status. 
CONCLUSION 
Our findings, taken in the context of previous observations, and the 
independent nature of this association between low 25(OH)D levels and 
acute coronary syndrome suggests that the relationship is not mediated 
by other risk factors, which indicates that vitamin D deficiency may 
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represent an important new CV risk factor. Because vitamin D deficiency 
can be readily determined by blood testing and treated by 
supplementation, clinical trials are urgently needed to determine 
whether this represents a causal association and whether vitamin D 
replacement therapy can reduce the associated increase in CV risk. 
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